Security key
929033207
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 40,448,699
- Total 13F value
- $716,851,001
- Share change
- +14,037,614
- SEC-reported price per share
- $17.84
- Number of holders
- 80
- Value change
- +$247,955,353
- Number of buys
- 57
- Number of sells
- 18
- Shares outstanding
- 54,372,965
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
80
Top holders
10
VOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Vor Biopharma Inc. SEC filings
Vor Biopharma Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 929033207
Recent filing periods:
Ownership snapshot
Top reported holders of VOR - Vor Biopharma Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Reprogrammed Interchange LLC
Disclosed value leader
Venrock Healthcare Capita...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 18%
13D/G row: Reprogrammed Interchange LLC
Showing 1-6 of 15 holder rows.
Quick read
Reprogrammed Interchange LLC leads the comparable SEC ownership view at 18%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Reprogrammed Interchange LLC's linked filing trail.
Comparable ownership
Top 5
Reprogrammed Interchange LLC
18%
TCG Crossover GP II, LLC
10%
ForGrowth III PA B.V.
10%
Venrock Healthcare Capital Partne...
9.9%
Verve Capital Ltd
9.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Reprogrammed Interchange LLC |
13D/G
3/4/5
10%+ Owner
|
18%
|
$48,045,191
1,204,442 shares
|
$0 | 15 Oct 2025 |
| TCG Crossover GP II, LLC |
3/4/5
13D/G
10%+ Owner · Chen Yu
|
10%
from 13D/G
|
$37,101,930
2,836,539 shares
|
— | 30 Mar 2026 |
| ForGrowth III PA B.V. |
13D/G
|
10%
|
$81,492,203
10,237,714 shares
|
+$25,772,203 | 18 Dec 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
9.9%
|
$91,763,980
5,083,877 shares
|
+$51,763,826 | 31 Mar 2026 |
| Verve Capital Ltd |
13D/G
Verve Capital Limited
|
9.3%
|
$90,236,860
4,999,272 shares
|
+$12,667,634 | 31 Mar 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.8%
|
$17,973,688
2,258,001 shares
|
$0 | 18 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
80
Shares
40,448,699
Rows available
80
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
80
Q1 2026 holders
80
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend